Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
Phase 3
Completed
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Drug: PlaceboDrug: Rezular 15mgDrug: Rezular
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AGI Therapeutics, Inc.
- Target Recruit Count
- 711
- Registration Number
- NCT00552565
- Locations
- 🇺🇸
PPD, Wilmington, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath